Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A new boric acid derivative and its pharmaceutical composition

A compound and pharmaceutical technology, applied in the field of anti-tumor compounds and their pharmaceutical compositions, can solve problems such as unmet clinical needs of therapeutic drugs

Active Publication Date: 2020-12-04
CHENGDU ORIGIN BIOTECH LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Colon cancer is also a high-incidence tumor type. Although there are a large number of therapeutic drugs and methods, high-value therapeutic drugs in this field are still unmet clinical needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A new boric acid derivative and its pharmaceutical composition
  • A new boric acid derivative and its pharmaceutical composition
  • A new boric acid derivative and its pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0167] Example 1 Preparation of compound I-1-1 of the present invention and its mannitol ester:

[0168]

[0169] (1) Dissolve 3 g (17.6 mmol) of the starting material (S-1-1) in 20 mL of dichloromethane solution, add 4.44 g (44.0 mmol) of NMM (N-methylmorpholine), and cool down to an internal temperature of 5 ℃, drop 2.29 g (21.1 mmol) of ethyl chloroformate, wait until the reaction is complete, and use the reaction solution for later use.

[0170] (2) Glycine 1.58g (21.1mmol) is dissolved in 30ml saturated sodium carbonate solution, is cooled to internal temperature 5 ℃, and step (1) gained reaction solution is added dropwise in this saturated sodium carbonate solution of glycine, internal temperature change control Within ±2°C, after the dropwise addition was completed, continue to stir at room temperature for 3h. Take the water layer, adjust the pH value to 2-3 with 15ml of dilute hydrochloric acid (2mol / ml), a solid precipitates, filter with suction, take the solid, a...

Embodiment 2

[0178] Example 2 Preparation of Compounds I-1-2, I-1-2-1, I-1-2-2, I-1-2-3, I-1-2-4 of the present invention

[0179]

[0180] Boric acid starting material (I-1-1) 5 grams (14.7mmol), diethanolamine (M2, molecular weight 105.14) 1.58 grams (15.0mmol), 20mL ethyl acetate, stirred overnight at room temperature, precipitated a white solid, filtered to obtain 4.8 gram compound I-1-2, yield 79%, namely 2-chloro-5-methyl-[(R)-1-[1,3,7,2]-dioxazepine-2-boryl- 3-Methyl-butyrocarboxamido]-methyl]-benzamide.

[0181] 1 H NMR (300 MHz, DMSO-d6) δ (ppm): 8.69 (brs, 1H), 7.35-7.39 (m, 2H), 7.25-7.29 (m, 1H), 6.95 (d, 1H, J=4.71Hz ), 6.59(m, 1H), 3.74-3.79(m, 2H), 3.67(m, 3H), 3.57(m, 1H), 3.13(m, 1H), 2.99(m, 2H), 2.73-2.78( m, 2H), 2.31 (m, 3H), 1.59 (m, 1H), 1.18-1.30 (m, 2H), 0.81 (m, 6H).

[0182] ESI m / z: 410.32[M+H] + .

[0183] The mass spectrum of compound I-1-2 is as followsfigure 1 shown.

[0184] Similar to the synthesis of compound I-1-2, the boronic acid starting mat...

Embodiment 3

[0194] Example 3 Preparation of compounds I-1-3 and I-1-3-1 of the present invention

[0195]

[0196] Dissolve 2.25 g (6.61 mmol) of the boric acid starting material (I-1-1) in 10 ml of ethyl acetate, add 0.92 g (6.94 mmol) of dipropanolamine (M3, molecular weight 133.19) while stirring at room temperature, and continue stirring for 2 h. A precious solid was precipitated, and 2.05 g of compound I-1-3 was obtained by filtration, with a yield of 71%.

[0197] ESI m / z: 436.42[M-H] - .

[0198] Similar to the synthesis of compound I-1-3, I-1-3-1 was prepared by reacting boronic acid starting material (I-1-1) with M3-1 tripropanolamine.

[0199]

[0200] ESI m / z: 518.31[M+Na] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention discloses a novel boric acid derivative and a pharmaceutical composition using the same, pertaining to the field of medicinal chemistry. The boric acid derivative is a compound represented by formula (I). The present invention further provides a use of the boric acid derivative in the preparation of an antitumor drug or a proteasome inhibitor drug. Specifically, the present invention provides a use of the boric acid derivative in the preparation of a proteasome chymotrypsin-like protease inhibitor drug, and a use in drugs for the prophylaxis and / or treatment of cancer such as multiple myeloma and colon cancer, providing a new choice for clinical screening and / or preparation of proteasome inhibitor drugs and drugs for cancer such as multiple myeloma and colon cancer, having wide application prospects.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and in particular relates to an antitumor compound and a pharmaceutical composition thereof. Background technique [0002] The ubiquitin-proteasome pathway-mediated protein degradation is an important mechanism for the body to regulate the level and function of intracellular proteins. Once the proteasome exceeds the normal level, it will lead to the weakening of growth inhibition, the reduction of apoptosis, and the promotion of angiogenesis, thereby triggering a variety of tumor diseases. Therefore, the proteasome is an important target for anticancer and other drugs. Proteasome inhibitors inhibit tumor cell growth and promote apoptosis by blocking cellular proteasome degradation. [0003] Multiple myeloma (multiple myeloma, MM) is a plasma cell carcinoma found in the bone marrow. In multiple myeloma, a group of plasma cells, or myeloma cells, transform into cancer cells and proliferate, mak...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07F5/02A61K31/69A61P35/00
CPCA61P35/00C07F5/025A61K31/69C07F5/02C07F5/04
Inventor 广兵阳泰董韧涵刘进谢建秦岭钟月玲
Owner CHENGDU ORIGIN BIOTECH LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com